Health ❯ Healthcare ❯ Pharmaceuticals

Drug Regulation

FDA FDA Decisions FDA Actions Mifepristone Compounding Pharmacies FDA Leadership Counterfeit Drugs FDA Oversight GLP-1 Drugs MHRA

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

The warning focuses on mass-marketed 'personalized' versions sold outside FDA review.

FDA Biologics Chief Vinay Prasad to Step Down at End of April

Delhi Crackdown on Cancer Medicines Flags 6 Firms for Violations

Hims & Hers Halts $49 Compounded Wegovy Pill as FDA Tightens GLP-1 Rules

Peru Orders Recall and Destruction of Sulfato Ferroso 300 mg Lot 2077104 After Quality Failure

Brazil Bans Unregistered Tirzepatide Brands and Retatrutide as Seizures Mount

CDSCO Flags 167 Drug Samples as Not of Standard Quality in December

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

Republicans Push to Restore In‑Person Rules for Abortion Pill at Fiery Senate Hearing

Telangana Orders Stop-Use of Almont-Kid Syrup After Ethylene Glycol Found

UK Regulator Orders Stronger Addiction Warnings on Benzodiazepines, Gabapentinoids and Z‑Drugs

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

FDA Installs Tracy Beth Hoeg as Acting CDER Director as Pazdur Files Retirement

Gilead Starts Shipping Twice-Yearly HIV Prevention Shot to Eswatini and Zambia

France’s Drug Regulator Orders Halt to ‘GLP‑1’ Patch Sales on Seven Websites

India Weighs Stricter Controls on Cough Syrup Sales After Contamination Deaths

UK Lawmaker Urges Crackdown as Illegal ‘Triple G’ Weight-Loss Jabs Spread Online

FDA Names Richard Pazdur to Lead Drug Review Center

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Senate Democrats Press FDA on Mifepristone Review After Court Strikes Down Restrictions